GRF.MC - Grifols, S.A.

MCE - MCE Verzögerter Preis. Währung in EUR

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan Sant Cugat del Valles
Barcelona 08174
34 93 571 05 00

BrancheDrug Manufacturers—General

Leitende Angestellte

Mr. Thomas H. GlanzmannExec. Chairman150kN/A1958
Mr. Raimon Grifols RouraCo-CEO & Exec. Vice-Chairman1,04MN/A1964
Mr. Víctor Grifols DeuCo-CEO & Exec. Director1,04MN/A1977
Mr. Alfredo Arroyo GuerraCFO & VPN/AN/A1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/AN/AN/A
Ms. Nuria Pascual LapeñaVP of Corp. Treasury, Risk Management Investor Relation & Sustainability OfficerN/AN/A1964
Mr. David Ian BellChief Corp. Devel., Legal & Data Protection OfficerN/AN/A1954
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/AN/A1956
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/AN/A1965
Ms. Montserrat Gaja LlamasChief HR OfficerN/AN/A1965
Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.


Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.s ISS Governance QualityScore, Stand 1. Juni 2023, lautet 4. Die grundlegenden Scores sind Audit: 2, Vorstand: 6, Shareholderrechte: 6, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.